Metformin found to be Effective and Safe for Obesity in Chil
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to assess the efficacy and safety of metformin for obesity in children and adolescents that suggested favourable outcomes with metformin. Researchers selected randomized controlled trials (RCTs) in which the efficacy and safety of metformin with lifestyle interventions was assessed, compared with a placebo with lifestyle interventions, in children and adolescents with obesity.

Two researchers independently extracted data and assessed quality. The primary outcomes were mean changes from baseline in BMI, BMI z score, homeostatic model assessment of insulin resistance, and gastrointestinal adverse effects.

Results:
--24 RCTs (1623 patients; range: 16 to 151) were included.

--Ages ranged from 4 to 19 years, and follow-up ranged from 2 months to 2 years.

--Metformin resulted in a modest decrease in BMI (range of mean values: -2.70 to 1.30 vs -1.12 to 1.90), BMI z score (range of mean values: -0.37 to -0.03 vs -0.22 to 0.15), and homeostatic model assessment of insulin resistance (range of mean values: -3.74 to 1.00 vs -1.40 to 2.66).

--Metformin resulted in a higher frequency of gastrointestinal adverse effects (range: 2% to 74% vs 0% to 42%).

Conclusively, with this systematic review of RCTs, it was suggested that metformin has modest but favorable effects on weight and insulin resistance and a tolerable safety profile among children and adolescents with obesity.

Source: https://pediatrics.aappublications.org/content/early/2021/02/17/peds.2020-1610?rss=1
Like
Comment
Share